- Press Releases
- Notices
Press Releases To List
-
- May.29.2025R & D
- Bristol Myers Squibb Receives European Commission Approval for the Subcutaneous Formulation of Opdivo® (nivolumab) Across Multiple Solid Tumor Indications
-
- May.28.2025R & D
- ONO PHARMA Presents Positive Results from Pivotal Trial in U.S. Patients with Relapsed or Refractory PCNSL at 2025 ASCO Annual Meeting
-
- May.19.2025R & D
- Bristol Myers Squibb Receives European Commission Approval for Perioperative Regimen of Neoadjuvant Opdivo® (nivolumab) and Chemotherapy Followed by Adjuvant Opdivo for Resectable, High-Risk Non-Small Cell Lung Cancer with PD-L1 Expression ≥1%
-
- May.08.2025Management / Finance
- Announcement on Financial Results for FY2024
-
- May.08.2025Management / Finance
- Notice regarding Differences in the Non-consolidated Financial Results between the Fiscal Year Ended March 31, 2025 and the Previous Fiscal Year
Notices To List
-
- May.28.2025Corporate
- Notice about Posting of R&D Day - ROMVIMZA - Script
-
- May.22.2025Corporate
- Notice to Convene the 77th Ordinary General Shareholders' Meeting
-
- May.13.2025Corporate
- Notice about Posting of the Business Result Meeting for FY2024 Script
-
- Mar.14.2025Corporate
- Notice about the Establishment of the ONO PHARMA Heritage Center
-
- Mar.10.2025Corporate
- Notice about Posting of the Sustainability Meeting Script
About
We Want to Deliver New Drugs
to the World with a Wish.
For more than 300 years since its foundation in 1717, working for people’s health.
Diseases still unconquered. Patients' wishes still unfulfilled.
ONO, with a wish to meet these medical needs, devotes all its efforts to drug discovery.
